The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death
Open accessAbstract
Background Germline mutations in BRCA1/2 and ATM have been associated with prostate cancer (PCa) risk. Objective To directly assess whether germline mutations in these three genes distinguish lethal from indolent PCa and whether they confer any effect on age at death. Design, setting, and participants A retrospective case-case study of 313 patients who died of PCa and 486 patients with low-risk localized PCa of European, African, and Chinese descent. Germline DNA of each of the 799 patients was sequenced for these three genes. Outcome measurements and statistical analysis Mutation carrier rates and their effect on lethal PCa were analyzed using the Fisher’s exact test and Cox regression analysis, respectively. Results and limitations The combined BRCA1/2 and ATM mutation carrier rate was significantly higher in lethal PCa patients (6.07%) than localized PCa patients (1.44%), p = 0.0007. The rate also differed significantly among lethal PCa patients as a function of age at death (10.00%, 9.08%, 8.33%, 4.94%, and 2.97% in patients who died ≤60 yr, 61–65 yr, 66–70 yr, 71–75 yr, and over 75 yr, respectively, p = 0.046) and time to death after diagnosis (12.26%, 4.76%, and 0.98% in patients who died ≤5 yr, 6–10 yr, and > 10 yr after a PCa diagnosis, respectively, p = 0.0006). Survival analysis in the entire cohort revealed mutation carriers remained an independent predictor of lethal PCa after adjusting for race and age, prostate-specific antigen, and Gleason score at the time of diagnosis (hazard ratio = 2.13, 95% confidence interval: 1.24–3.66, p = 0.004). A limitation of this study is that other DNA repair genes were not analyzed. Conclusions Mutation status of BRCA1/2 and ATM distinguishes risk for lethal and indolent PCa and is associated with earlier age at death and shorter survival time. Patient summary Prostate cancer patients with inherited mutations in BRCA1/2 and ATM are more likely to die of prostate cancer and do so at an earlier age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationClinVar: public archive of relationships among sequence variation and human phenotype
Landrum, M. J., Lee, J. M., Riley, G. R., Jang, W., Rubinstein, W. S., Church, D. M., & Maglott, D. R. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1113 · Cited by 3,516
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing
Green, R. C., Berg, J. S., Grody, W. W., Kalia, S. S., Korf, B. R., Martin, C. L., McGuire, A. L., Nussbaum, R. L., O’Daniel, J. M., Ormond, K. E., et al. (2013) · Genetics in Medicine · doi:10.1038/gim.2013.73 · Cited by 2,541
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Human Gene Mutation Database (HGMD®): 2003 update: HGMD 2003 UPDATE
Stenson, P. D., Ball, E. V., Mort, M., Phillips, A. D., Shiel, J. A., Thomas, N. S. T., Abeysinghe, S., Krawczak, M., & Cooper, D. N. (2003) · Human Mutation · doi:10.1002/humu.10212 · Cited by 1,829
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Self-citationCancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Castro, E., Goh, C., Olmos, D., Saunders, E., Leongamornlert, D., Tymrakiewicz, M., Mahmud, N., Dadaev, T., Govindasami, K., Guy, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1882 · Cited by 850
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer
The Breast and Prostate Cancer Cohort Consortium (BPC3), Al Olama, A. A., The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, The COGS (Collaborative Oncological Gene-environment Study) Consortium, The GAME-ON/ELLIPSE Consortium, Kote-Jarai, Z., Berndt, S. I., Conti, D. V., Schumacher, F., Han, Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.3094 · Cited by 455
Self-citationCancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature
Liede, A., Karlan, B. Y., & Narod, S. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.055 · Cited by 407
Collaborators, T. U., Kote-Jarai, Z., Leongamornlert, D., Saunders, E., Tymrakiewicz, M., Castro, E., Mahmud, N., Guy, M., Edwards, S., O'Brien, L., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.383 · Cited by 399
Castro, E., Goh, C., Leongamornlert, D., Saunders, E., Tymrakiewicz, M., Dadaev, T., Govindasami, K., Guy, M., Ellis, S., Frost, D., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.022 · Cited by 368
Two Percent of Men with Early-Onset Prostate Cancer Harbor Germline Mutations in the BRCA2 Gene
Edwards, S. M., Kote-Jarai, Z., Meitz, J., Hamoudi, R., Hope, Q., Osin, P., Jackson, R., Southgate, C., Singh, R., Falconer, A., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/345310 · Cited by 366
NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016
Carroll, P. R., Parsons, J. K., Andriole, G., Bahnson, R. R., Castle, E. P., Catalona, W. J., Dahl, D. M., Davis, J. W., Epstein, J. I., Etzioni, R. B., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0060 · Cited by 342
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
Gallagher, D. J., Gaudet, M. M., Pal, P., Kirchhoff, T., Balistreri, L., Vora, K., Bhatia, J., Stadler, Z., Fine, S. W., Reuter, V., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2871 · Cited by 301
Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers
Tryggvadottir, L., Vidarsdottir, L., Thorgeirsson, T., Jonasson, J. G., Olafsdottir, E. J., Olafsdottir, G. H., Rafnar, T., Thorlacius, S., Jonsson, E., Eyfjord, J. E., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm005 · Cited by 231
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
Collaborators, T. I. A. E., Mitra, A., Fisher, C., Foster, C. S., Jameson, C., Barbachanno, Y., Bartlett, J., Bancroft, E., Doherty, R., Kote-Jarai, Z., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604132 · Cited by 173
BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews
Kirchhoff, T., Kauff, N. D., Mitra, N., Nafa, K., Huang, H., Palmer, C., Gulati, T., Wadsworth, E., Donat, S., Robson, M. E., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0604 · Cited by 165
Rapid progression of prostate cancer in men with a BRCA2 mutation
the Hereditary Breast Cancer Study Group, Narod, S. A., Neuhausen, S., Vichodez, G., Armel, S., Lynch, H. T., Ghadirian, P., Cummings, S., Olopade, O., Stoppa-Lyonnet, D., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604453 · Cited by 162
Risbridger, G. P., Taylor, R. A., Clouston, D. R., Sliwinski, A., Thorne, H., Hunter, S. M., Li, J., Mitchell, G., Murphy, D. G., Frydenberg, M., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.08.007 · Cited by 149
Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers
Jóhannsson, Ó. Þ., Loman, N., Møller, H., Kristoffersson, U., Borg, Å., & Olsson, H. L. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00135-5 · Cited by 122
BRCA1 and BRCA2 have a limited role in familial prostate cancer.
Sinclair, C. S., Berry, R. M., Schaid, D. J., Thibodeau, S. N., & Couch, F. J. (2000) · PubMed · Cited by 69
Germline Mutations in theBRCA2Gene and Susceptibility to Hereditary Prostate Cancer
Agalliu, I., Kwon, E. M., Zadory, D., McIntosh, L. M., Thompson, J., Stanford, J. L., & Ostrander, E. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2164 · Cited by 41
Hart, S. N., Ellingson, M. S., Schahl, K. A., Vedell, P. T., Carlson, R. E., Sinnwell, J. P., Barman, P., Sicotte, H., Eckel‐Passow, J. E., Wang, L., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010332 · Cited by 39
Prostate cancer risk-associated genetic markers and their potential clinical utility
Xu, J., Sun, J., & Zheng, S. L. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2013.42 · Cited by 35
Self-citationGenome-Wide Association Study of Prostate Cancer–Specific Survival
Szulkin, R., Karlsson, R., Whitington, T., Aly, M., Grönberg, H., Eeles, R. A., Easton, D. F., Kote‐Jarai, Z., Olama, A. A. A., Benlloch, S., et al. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0543 · Cited by 29
Cited by
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Phillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., Rowe, S. P., Ross, A. E., Gorin, M. A., Deville, C., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0147 · Cited by 1,159
Self-citationDaly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792
Metadata
- Authors
- Na, R., Zheng, S. L., Han, M., Yu, H., Jiang, D., Shah, S., Ewing, C. M., Zhang, L., Novakovic, K., Petkewicz, J., Gulukota, K., Helseth Jr, D. L., Quinn, M., Humphries, E., Wiley, K. E., Isaacs, S. D., Wu, Y., Liu, X., Zhang, N., Wang, C.-H., Khandekar, J., Hulick, P. J., Shevrin, D. H., Cooney, K. A., Shen, Z., Partin, A. W., Carter, H. B., Carducci, M. A., Eisenberger, M. A., Denmeade, S. R., McGuire, M., Walsh, P. C., Helfand, B. T., Brendler, C. B., Ding, Q., Xu, J., & Isaacs, W. B.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 71
- Issue
- 5
- Pages
- 740-747
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2567290427
- Cited by
- 343
- References
- 28
- FWCI
- 20.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.